Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

Open access
Akhmetshina, Alfiya, Venalis, Paulius, Dees, Clara, Busch, Nicole, Zwerina, Jochen, Schett, Georg, Distler, Oliver, Distler, Jörg H. W. · 2009 · Arthritis & Rheumatism

Abstract

Objective: Imatinib is a small‐molecule tyrosine kinase inhibitor capable of selective, dual inhibition of the transforming growth factor β and platelet‐derived growth factor (PDGF) pathways. Imatinib has previously been shown to prevent the development of inflammation‐driven experimental fibrosis when treatment was initiated before administration of the profibrotic stimulus. The aim of this study was to confirm the efficacy of imatinib in a murine model of systemic sclerosis (SSc) that is less driven by inflammation and to investigate whether imatinib is also effective for the treatment of established fibrosis. Methods: The tight skin 1 (TSK‐1) mouse model of SSc was used to evaluate the antifibrotic effects of imatinib in a genetic model of the later stages of SSc. In addition, the efficacy of imatinib for the treatment of preestablished fibrosis was analyzed in a modified model of bleomycin‐induced dermal fibrosis in which the application of bleomycin was prolonged and the onset of treatment was late. Results: Treatment with imatinib reduced dermal and hypodermal thickening in TSK‐1 mice and prevented the differentiation of resting fibroblasts into myofibroblasts. In the model of preestablished dermal fibrosis, imatinib not only stopped further progression of fibrosis but also induced regression of preexisting dermal fibrosis, with a reduction in dermal thickness below pretreatment levels. Conclusion: These results indicate that combined inhibition of the tyrosine kinase c‐Abl and PDGF receptor might be effective in the later, less inflammatory stages of SSc and for the treatment of established fibrosis. Thus, imatinib might be an interesting candidate for clinical trials in patients with longstanding disease and preexisting tissue fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.24186

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 212

Metadata

Authors
Akhmetshina, A., Venalis, P., Dees, C., Busch, N., Zwerina, J., Schett, G., Distler, O., & Distler, J. H. W.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2008-12-30
Volume
60
Issue
1
Pages
219-224
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W1990842725
Cited by
212
References
1
FWCI
15.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.